Valneva/Emergent BioSolutions' Candidate Zika Vaccine Shows Early Clinical Promise

 
• By John Davis

A European/US company collaboration has reported encouraging safety and immunogenicity in early clinical studies with an alum-adjuvanted Zika vaccine based on inactivated whole virus.  

Mosquito
The bite of the Aedes mosquito transmits Zika virus to humans. • Source: Shutterstock

More from Clinical Trials

More from R&D